about
RUCAM in Drug and Herb Induced Liver Injury: The UpdateEnoxaparin-Induced Liver Injury: Case Report and Review of the Literature and FDA Adverse Event Reporting System (FAERS)Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting systemDrug-induced liver injury: Towards early prediction and risk stratificationDirect Oral Anticoagulants in Cirrhosis.Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation.Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk.A Rare Case of Rivaroxaban Causing Delayed Symptomatic Hepatocellular Injury and Hyperbilirubinemia.Hepatotoxicity of New Oral Anticoagulants (NOACs).Acute Liver Failure after Initiation of Rivaroxaban: A Case Report and Review of the Literature.Direct oral anticoagulants in rare venous thrombosis.Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature.Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis.Portal vein thrombosis in patients with cirrhosis: underdiagnosis and undertreatment?Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: Systematic review and meta-analysis.
P2860
Q26771817-24E0DD1A-530E-4B87-A862-8A8B96E9D9CDQ28074812-97F82FBC-5AAD-4B69-9921-33D88B8EF403Q28257188-2555E418-B3A4-4BD7-B10F-C4C0D398BF55Q28468389-52BE4410-1C95-4AE8-B787-B0C444CCCBBCQ30277086-F56F9EEE-B47F-4214-B87A-2587CD66E522Q30277819-D3371629-C047-4DB3-BFA1-1F6AEA760BDCQ35819331-AAD6B7EA-F489-4246-9125-0641B85DB3E4Q37637749-E869B5E3-A2C8-4E61-8AD0-0A17379A43BDQ38542198-79AA3D3C-99E0-49C1-A21A-8AEC6BC68C1AQ38647192-E16342A0-A2D5-47C6-988B-0822F4B7DB0AQ38732728-4764AB09-2E24-4F50-99ED-B1B6A53D7D0CQ38824550-59C9FBD6-73E0-4A7D-A7BD-9F765E2C4451Q39251865-95E22186-D346-4A73-9ED9-D91A255B5330Q53783646-0DB1FD6B-D97E-4322-9173-A11F67427725Q55065699-81AAA100-F496-4BE3-8410-1287958175B8
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Rivaroxaban postmarketing risk of liver injury
@ast
Rivaroxaban postmarketing risk of liver injury
@en
Rivaroxaban postmarketing risk of liver injury
@nl
type
label
Rivaroxaban postmarketing risk of liver injury
@ast
Rivaroxaban postmarketing risk of liver injury
@en
Rivaroxaban postmarketing risk of liver injury
@nl
prefLabel
Rivaroxaban postmarketing risk of liver injury
@ast
Rivaroxaban postmarketing risk of liver injury
@en
Rivaroxaban postmarketing risk of liver injury
@nl
P2093
P1476
Rivaroxaban postmarketing risk of liver injury
@en
P2093
Bruno Stieger
Caroline Schmidt
David F Niedrig
Gerd A Kullak-Ublick
Mathias Budmiger
Sandra Hürlimann
Stefan Russmann
P304
P356
10.1016/J.JHEP.2014.03.026
P407
P577
2014-08-01T00:00:00Z